Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 12:15 save search
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
ALKS | $24.26 0.79% 0.78% 1.2M
|
Health Technology
|
| O: -1.59%
H: 1.86%
C: -1.05%
treatment neurodegenerative neurological phase 1 phase 2
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-11-09 (Crawled : 12:15) - globenewswire.com
CMPS | $8.235 -1.5% -1.52% 350K
|
Health Technology
|
| O: -17.57%
H: 3.31%
C: -11.45%
treatment positive therapy results topline depression trial comp360 psilocybin
Predictive Analytics Solutions Create New Opportunities for Life Sciences to Address Delayed Diagnosis and other Challenges in Multiple Sclerosis Treatment
Published: 2021-11-05 (Crawled : 12:15) - globenewswire.com
OPRX A | $8.95 -1.54% -1.56% 150K
|
Technology Services
|
| O: -0.44%
H: 1.06%
C: -1.65%
multiple sclerosis treatment life science sclerosis analytics diagnostic
Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease
Published: 2021-11-03 (Crawled : 12:15) - globenewswire.com
ALNA | $0.075 -12.0%
|
Health Technology
|
| O: 22.35%
H: 12.5%
C: -3.85%
disease treatment fda fast track fast track designation kidney designation
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
Published: 2021-10-29 (Crawled : 12:15) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 2.31%
H: 0.0%
C: 0.0%
treatment phase 3 depression major depressive disorder
Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
Published: 2021-10-28 (Crawled : 12:15) - globenewswire.com
SPRO | $1.435 2.14% 2.09% 120K
|
Health Technology
|
| O: 0.18%
H: 7.08%
C: 7.08%
new drug treatment fda application drug injection infections
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy– Pasithea Clinics
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
KTTA | $6.76 -1.19% 730
|
|
| O: 2.95%
H: 43.37%
C: 6.09%
treatment therapy ketamine depression
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Published: 2021-10-15 (Crawled : 12:15) - globenewswire.com
ASND | $145.17 2.16% 2.11% 220K
|
Health Technology
|
| O: 0.85%
H: 0.48%
C: -0.85%
treatment fda growth hormone growth hormone fda approval
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock Tuesday, October 19th @ 8:00 am Eastern Time
Published: 2021-10-14 (Crawled : 12:15) - biospace.com/
WINT | $5.52 1.28% 1.27% 81K
|
Health Technology
|
| O: 1.32%
H: 1.74%
C: -0.87%
treatment heart cardio
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Published: 2021-10-14 (Crawled : 12:15) - biospace.com/
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: -3.38%
multiple sclerosis treatment phase 2 europe sclerosis research trial
Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Published: 2021-10-13 (Crawled : 12:15) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: -10.11%
multiple sclerosis treatment europe sclerosis research preclinical pre-clinical
Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results
Published: 2021-10-12 (Crawled : 12:15) - biospace.com/
WINT | $5.52 1.28% 1.27% 81K
|
Health Technology
|
| O: 1.3%
H: 1.28%
C: -2.56%
treatment eye cardiologists results drug research cardio
Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
Published: 2021-10-08 (Crawled : 12:15) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
treatment fda fda approval approval application
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-10-07 (Crawled : 12:15) - globenewswire.com
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: 0.99%
H: 5.99%
C: 2.95%
treatment immunotherapy therapy cancer preclinical pre-clinical
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published: 2021-10-05 (Crawled : 12:15) - biospace.com/
BHVN | News 0 d | $39.61 3.34% 0.0% 2.1M
|
Health Technology
|
| O: 3.9%
H: 2.03%
C: -3.89%
treatment migraine
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
Published: 2021-10-04 (Crawled : 12:15) - prnewswire.com
IKT | $1.57 14.6% 12.74% 78K
|
Health Technology
|
| O: 2.32%
H: 2.77%
C: -1.77%
disease treatment results parkinson ikt-148009
CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2021-09-30 (Crawled : 12:15) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.64%
H: 1.89%
C: -5.08%
CNSP | News | $0.201 0.95% 0.95% 120K
|
Health Technology
|
| O: -3.75%
H: 3.9%
C: -3.25%
berubicin treatment fda potential fast track drug designation glioblastoma
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: -1.28%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -7.01%
H: 2.22%
C: -1.77%
alcohol use disorder treatment phase 1 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.